Ownership history in FEDERATED HERMES, INC. Β· 64 quarters on record
This page tracks every 13F SEC filing in which FEDERATED HERMES, INC. reported a position in CORCEPT THERAPEUTICS INC COM (CORT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π FEDERATED HERMES, INC. outperformed the S&P 500 by +23.4% annually on this CORT position. Timing score: 36% (20/56 decisions correct). Average cost basis: $5.27. Maximum drawdown during holding period: β68.2%.
π₯ Exceptional β beat the S&P 500 by 23.4% per year on this position.
63 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
20 of 56 add/trim decisions correct
Best entry: $1.73 (2013 Q2) Β· Worst: $50.39 (2024 Q4)
πͺ Held through 9 major drawdowns (>20%). Diamond-hands conviction.
24 adds Β· 33 trims. Bought during 9 of 26 down-price quarters. π Predominantly trimming β distribution phase.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size